Sciensus and Novocure launch UK home TTFields pathway for private patients

Sciensus has agreed to deliver a fully integrated home treatment pathway for eligible UK private patients prescribed Tumour Treating Fields therapy, starting with access to Novocure’s cancer treatment program. The move expands at-home oncology care for glioblastoma, mesothelioma and non-small cell lung cancer, with insurer support already in place for some patients.

Why it matters: - The agreement expands access to Tumour Treating Fields therapy outside the hospital setting for eligible private patients in the UK. - The home-based model combines specialist oncology care, device support and ongoing patient support in one pathway. - The service may make treatment easier to manage for patients and give consultants a practical way to maintain care after diagnosis.

What happened: - Sciensus announced a new agreement with Novocure to deliver a fully integrated, consultant-led home treatment pathway for eligible private patients prescribed TTFields therapy. - The service is available nationally across the UK. - The pathway covers Novocure’s TTFields therapy for glioblastoma, mesothelioma and non-small cell lung cancer. - The agreement also allows patients to access SACT, or systemic anti-cancer treatment, when it is appropriate to the Novocure treatment and approved indication.

The details: - TTFields are alternating electric fields that disrupt processes critical for cancer cell division and survival, leading to cancer cell death without significantly affecting healthy cells. - A wearable medical device delivers TTFields non-invasively through arrays placed on the skin. - Sciensus will combine specialist oncology care, nationwide homecare services and ongoing patient support in the pathway. - The service builds on Sciensus’ experience in delivering complex cancer treatments at home through oncology nurses, clinical nurse specialists, pharmacists, logistics and digital care pathways. - The pathway includes dedicated device support specialists alongside specialist clinical care. - Leading private medical insurers already support access, and additional funding arrangements are available case by case. - For CE-marked intended purposes, contraindications and other safety information, Novocure directs readers to the product-specific User Manual.

Between the lines: - The partnership signals growing interest in home-based delivery models for advanced cancer therapies. - Sciensus is positioning its cancer services around consultant-led care that extends beyond the hospital. - Novocure is using the partnership to widen access to TTFields for eligible patients in the UK.

What's next: - Eligible private patients will be able to access the new pathway nationwide. - Insurer participation and case-by-case funding arrangements may broaden use over time. - Sciensus will continue expanding its private cancer services around home-based, consultant-led care.

The bottom line: - The Sciensus-Novocure deal brings a complex oncology therapy into a more coordinated homecare model for eligible UK private patients.